Douglas A Hooper

US Patent:

6890532, May 10, 2005

Filed:

May 4, 2001

Appl. No.:

09/848832

Inventors:

Douglas C. Hooper - Medford NJ, US
Bernhard Dietzschold - Newtown Square PA, US

Assignee:

Thomas Jefferson University - Philadelphia PA

International Classification:

A61K039/42

US Classification:

4241471, 4241421, 5303883, 53038815

Abstract:

Human monoclonal rabies virus neutralizing antibodies represent a safe and efficacious post-exposure prophylactic therapy for individuals exposed to a rabies virus. The nucleic acid and encoded amino acid sequences of the heavy and light chain immunoglobulins of human monoclonal rabies virus neutralizing antibodies, and their use, is described.

US Patent:

7071319, Jul 4, 2006

Filed:

Aug 21, 2002

Appl. No.:

10/225108

Inventors:

Douglas Craig Hooper - Medford NJ, US
Bernhard Dietzschold - Newton Square PA, US

Assignee:

Thomas Jefferson University - Philadelphia PA

International Classification:

C07H 21/04

US Classification:

536 2353, 4353201, 435339

Abstract:

Recombinant antibodies are disclosed. The nucleic acid and encoded amino acid sequences of the heavy and light chain immunoglobulins of human monoclonal rabies virus neutralizing antibodies, and their use, are described.

US Patent:

20040013672, Jan 22, 2004

Filed:

Jun 13, 2003

Appl. No.:

10/461148

Inventors:

Douglas Hooper - Medford NJ, US
Bernhard Dietzschold - Newtown Square PA, US

Assignee:

Thomas Jefferson University - Philadelphia PA

International Classification:

A61K039/42

US Classification:

424/159100

Abstract:

Methods and compositions are provided for the use of rabies virus-neutralizing antibodies for postexposure prophylactic treatment of subjects exposed to rabies virus. Compositions comprising mixtures of rabies virus-neutralizing antibodies, as well as nucleotide and amino acid sequences encoding these antibodies, can be used in the treatment of subjects exposed to rabies virus. The invention also provides methods of producing recombinant rabies virus-neutralizing human antibodies in mammalian cells using recombinant expression vectors.

US Patent:

20060216300, Sep 28, 2006

Filed:

Jun 10, 2004

Appl. No.:

10/560299

Inventors:

Douglas Hooper - Medford NJ, US
Bernhard Dietzschold - Newtown Square PA, US

Assignee:

Thomas Jefferson University - Philadelphia PA

International Classification:

A61K 39/42
G01N 33/53

US Classification:

424159100, 435007100

Abstract:

Methods and compositions are provided for the use of rabies virusneutralizing antibodies for postexposure prophylactic treatment of subjects exposed to rabies virus. Compositions comprising mixtures of rabies virusneutralizing antibodies, as well as nucleotide and amino acid sequences encoding these antibodies, can be used in the treatment of subjects exposed to rabies virus. The invention also provides methods of producing recombinant rabies virus-neutralizing human antibodies in mammalian cells using recombinant expression vectors.

US Patent:

61299219, Oct 10, 2000

Filed:

Dec 5, 1995

Appl. No.:

8/567713

Inventors:

Douglas Craig Hooper - Medford NJ
Bernhard Dietzschold - Newtown Square PA
Hilary Koprowski - Wynnewood PA

Assignee:

Thomas Jefferson University - Philadelphia PA

International Classification:

A61K 3929
A61K 39205
A61K 4700
C07K 1400

US Classification:

4242241

Abstract:

Methods of enhancing an antigen-induced immune response through use of a ribonucleocapsid complex are provided. Composition containing a ribonucleocapsid complex and an antigen which are capable of enhancing the immune response to the antigen are also provided.

US Patent:

20220195440, Jun 23, 2022

Filed:

Mar 27, 2020

Appl. No.:

17/599023

Inventors:

- Philadelphia PA, US
Douglas C. Hooper - Medford NJ, US

International Classification:

C12N 15/113
G01N 33/574
A61K 31/495

Abstract:

The present disclosure relates to compositions and methods for treating cancers using antisense (AS) nucleic acids directed against Insulin-like Growth Factor 1 Receptor (IGF-1R). The AS may be administered to the patients systemically, or may be used to produce an autologous cancer cell vaccine. In some embodiments, the AS are provides in an implantable irradiated biodiffusion chamber comprising tumor cells and an effective amount of the AS. The chambers are irradiated and implanted in the abdomem of subjects and stimulate an immune response that attacks tumors distally. The compositions and methods disclosed herein may be used to treat many different kinds of cancer, for example glioblastoma. In some embodiments, the method are provided to predict the effectiveness of antisense (AS) nucleic acids directed against Insulin-like Growth Factor 1 Receptor (IGF-1R) in a subject.

US Patent:

20210389329, Dec 16, 2021

Filed:

Oct 29, 2019

Appl. No.:

17/289499

Inventors:

- Philadelphia PA, US
Douglas Craig HOOPER - Medford NJ, US
Timothy Chao - Philadelphia PA, US
Ana María CÁRDENAS CAICEDO - Philadelphia PA, US

International Classification:

G01N 33/68
G01N 33/574
C12Q 1/6883
C12Q 1/6886
C12Q 1/6888

Abstract:

The present invention provides compositions and methods for discriminating infectious from non-infectious CNS disorders, and providing appropriate treatment thereof.

US Patent:

20210060055, Mar 4, 2021

Filed:

Sep 15, 2020

Appl. No.:

17/020879

Inventors:

- Philadelphia PA, US
Douglas C. Hooper - Medford NJ, US

International Classification:

A61K 31/7105
C12N 15/113
A61K 31/713
A61P 35/00
A61K 39/00

Abstract:

The present disclosure relates to compositions and methods for treating cancers using antisense (AS) nucleic acids directed against Insulin-like Growth Factor 1 Receptor (IGF-1R). The AS may be administered to the patients systemically, or may be used to produce an autologous cancer cell vaccine. In embodiments, the AS are provided in an implantable irradiated biodiffusion chamber comprising tumor cells and an effective amount of the AS. The chambers are irradiated and implanted in the abdomen of subjects and stimulate an immune response that attacks tumors distally. The compositions and methods disclosed herein may be used to treat many different kinds of cancer, for example glioblastoma.